Part 9: International Regulations: Comparing EU MDR and US FDA

Two Giants in the Global Market: Regulatory Conflicts and Compliance Strategies

One of the biggest challenges for medical device manufacturers is complying with the differing regulatory systems enforced by the two largest markets in the world: the European Union (EU) and the United States (US). The EU’s new Medical Device Regulation (MDR) and the system managed by the US Food and Drug Administration (FDA) show significant differences in their core philosophies and requirements. Understanding these differences is vital for a global market entry strategy.

1. Key Differences in Risk Classification

While both the FDA and MDR classify devices based on risk levels, their underlying logic and resulting classifications differ:

2. Critical Divergence in Regulatory Pathways

The device’s class directly determines the approval process (CE Mark or Premarket Approval).

Medium-Risk Devices (FDA Class II vs. MDR Class IIa/IIb)

• FDA 510(k) (Premarket Notification): The standard route for medium-risk devices in the FDA is to prove that the device is “substantially equivalent” to a legally marketed predicate device. This typically does not require extensive new clinical data.
• MDR Class IIa/IIb: These devices are subject to Notified Body (NB) oversight under the MDR. The NB conducts a Quality Management System (QMS) audit and Technical Documentation assessment. Crucial Note: While many MDR Class IIa/IIb devices can be approved via FDA 510(k), the MDR may simultaneously drive more demanding clinical and PMCF programs for the same product.

High-Risk Devices (FDA Class III vs. MDR Class III)

• FDA PMA (Premarket Approval): The most stringent route. Requires standalone scientific evidence of safety and efficacy. No predicate comparison is used.
• MDR Class III: Requires QMS audit and Technical Documentation assessment. Additionally, Clinical Evaluation Consultation (Article 54) may be mandatory for specific implantable devices.

3. Regulatory Conflicts and Strategic Takeaways

The biggest conflict between these two systems arises in the clinical evidence obligation, particularly for medium-to-high-risk devices (MDR IIa/IIb).

• Clinical Data Burden: The MDR tends to demand significantly more clinical data for the same device than the FDA. While a claim of equivalence via FDA 510(k) may suffice, the MDR may require new clinical investigations or much more extensive PMCF data to support the CER.
• Avoid Mechanical Conversion: It is a mistake to try to mechanically convert an MDR class to an FDA class. The regulatory strategy must always start from the device’s intended use and the specific risk requirements of the relevant market.
• Software and Diagnostics: For Software as a Medical Device (SaMD) and In Vitro Diagnostic (IVD) devices, the MDR often requires assuming a higher risk class (frequently IIa/IIb) than the FDA.

MPH CTC’s Global Regulatory Expertise

At MPH CTC, we deeply understand both major regulatory systems. We offer manufacturers solutions that meet the requirements of both markets with a single, integrated clinical strategy:

• Unified Clinical Strategy: Clinical investigations designed to meet the high clinical evidence demands of the MDR are simultaneously optimized to provide the safety and efficacy data required by the FDA.
• Speed and Efficiency: By effectively managing the MDR’s challenging CER and PMCF programs, we shorten the time it takes for your device to enter both the EU and US markets.

References

[1] Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on medical devices.
[2] U.S. Food and Drug Administration (FDA) – Device Classification.FDA.gov.
[3] MDCG 2020-5 Guidance on clinical evaluation – equivalence.European Commission.